Moderna (NASDAQ:MRNA) is back in the headlines after phase three success for what's being called a cancer vaccine, built on the same mRNA technology that powered its Covid vaccine. We discuss just how significant it is that this treatment has gotten this far in trials, why the pandemic accelerated mRNA research faster than anyone expected, and why the commercial realities of personalized medicine, similar to the challenges facing CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals (NASDAQ:VRTX) with their multi million dollar sickle cell treatment, could complicate scalability even if the science works.
We make the case for why investing in a company trying to cure previously unsolvable diseases is worth serious consideration for stock investors, even beyond the pure economics, and why crossing a scientific milestone like this can open the floodgates for the rest of the biotech industry.
Then we shift to Uber (NYSE:UBER) and the case for why the robotaxi race may not be as simple as Waymo good, Uber bad. Rather than spending billions building its own autonomous vehicle fleet, Uber is positioning itself as the aggregator that Waymo, Zoox, Baidu and a growing list of AV players plug into. We break down CEO Dara Khosrowshahi's argument that the highest utilization operator will have the lowest cost of capital, and count the wave of robotaxi partnerships announced over just the last four months.
We close out on why this is not a simple binary bet, how Uber's ride hailing and delivery business has quietly become far more profitable in recent years, and why autonomous driving commoditization could actually favor Uber's asset light model as the technology scales globally.
Podden och tillhörande omslagsbild på den här sidan tillhör
MyWallSt. Innehållet i podden är skapat av MyWallSt och inte av,
eller tillsammans med, Poddtoppen.
